We are thrilled to see DNlite's predictive technology increasingly adopted by primary care clinics across Taiwan, delivering true precision medicine to patients with diabetes.
Recently, Dr. Hung-Lin Chen, President of the Taiwan Primary Care Diabetes Association, was featured in an exclusive interview with Hello Yishi (a leading health media platform) to discuss the paradigm shift in combating Chronic Kidney Disease (CKD).
In the interview, Dr. Chen highlighted a critical message: "We must transition from passive treatment to proactive prediction." He emphasized how innovative biomarkers like DNlite empower primary care physicians to overcome the diagnostic blind spots of traditional tests, identifying high-risk patients long before irreversible structural damage occurs.
????️ Watch the highlight reel (Mandarin) to see how DNlite is changing the game in primary care:
* Facebook:https://www.facebook.com/share/1C5E1mJbWN/
* Youtube:https://www.youtube.com/watch?v=26xnJFSDXpA
* Eventsite:https://helloyishi-event.com/event.php?id=10
Related News
BPM’s DNlite-IVD103 Granted Regulatory Approval in Thailand, Marking Its Third Global Market Entry
BPM’s DNlite-IVD103 Granted Regulatory Approval in Thailand, Marking Its Third Global Market Entry
2023/10/16
Press
BPM's DNlite-IVD103 Secures MDA Approval in Malaysia
Expanding Southeast Asian Footprint
2020/08/31
Press
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
2026/06/08
Press